Fig. 3

The fluctuating seroprevalence of HTLV infection among blood donors in 2016 to 2018. All the data from provinces or cities with a confirmed HTLV-1/2 infection in the 3 years were shown. The nationwide prevalence of anti-HTLV-1/2 antibody gradually reduced from 5.016/100,000 in 2016 and 4.951/100,000 in 2017 to 3.469/100,000 in 2018